161 related articles for article (PubMed ID: 36304630)
21. A Case of Thrombotic Thrombocytopenic Purpura and ST-Elevation Myocardial Infarction: An Unusual Correlation.
Omole AE; Ali A; Ogunniyi KE; Waqar D; Tobalesi O; Rahim O; Awosika A
Cureus; 2023 Mar; 15(3):e36039. PubMed ID: 37056547
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
He J; Qi J; Han H; Xu X; Li X; Song X; Han Y
Expert Rev Hematol; 2023 May; 16(5):377-385. PubMed ID: 37045600
[TBL] [Abstract][Full Text] [Related]
23. Successful Treatment of Refractory Thrombotic Thrombocytopenic Purpura (TTP) With Caplacizumab: A Case Report.
Pramanik D; Bhardwaj D; Karmani VK; Raval GG; Kutlar A
Cureus; 2023 Jul; 15(7):e42423. PubMed ID: 37637544
[TBL] [Abstract][Full Text] [Related]
24. Real-world experience with caplacizumab in the management of acute TTP.
Dutt T; Shaw RJ; Stubbs M; Yong J; Bailiff B; Cranfield T; Crowley MP; Desborough M; Eyre TA; Gooding R; Grainger J; Hanley J; Haughton J; Hermans J; Hill Q; Humphrey L; Lowe G; Lyall H; Mohsin M; Nicolson PLR; Priddee N; Rampotas A; Rayment R; Rhodes S; Taylor A; Thomas W; Tomkins O; Van Veen JJ; Lane S; Toh CH; Scully M
Blood; 2021 Apr; 137(13):1731-1740. PubMed ID: 33150355
[TBL] [Abstract][Full Text] [Related]
25. Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry.
Agosti P; De Leo P; Capecchi M; Ferrari B; Mancini I; Gattillo S; Trisolini SM; Rinaldi E; Podda GM; Prezioso L; Salutari P; Facchini L; Caramazza D; Tolomelli G; Artoni A; Peyvandi F
Res Pract Thromb Haemost; 2023 Aug; 7(6):102185. PubMed ID: 37720483
[TBL] [Abstract][Full Text] [Related]
26. Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange.
Kühne L; Knoebl P; Eller K; Thaler J; Sperr WR; Gleixner KV; Osterholt T; Kaufeld JK; Menne J; Buxhofer-Ausch V; Mühlfeld AS; Seelow E; Schreiber A; Todorova P; Cukoski S; Jabs WJ; Özcan F; Gäckler A; Schönfelder K; Seibert FS; Westhoff TH; Schwenger V; Eichenauer DA; Völker L; Brinkkoetter P
Blood; 2024 Jun; ():. PubMed ID: 38838300
[TBL] [Abstract][Full Text] [Related]
27. ST-Segment-Elevation Myocardial Infarction Unmasking Underlying Systemic Lupus Erythematosus or Representing Thrombotic Thrombocytopenic Purpura? Report of a Challenging Case.
Ghodsi S; Jenab Y; Mohebi M; Kamranzadeh H; Mohammadi Z
J Tehran Heart Cent; 2021 Apr; 16(2):84-88. PubMed ID: 35082877
[TBL] [Abstract][Full Text] [Related]
28. Early response to caplacizumab and rituximab after anaphylaxis to Octaplas plasma in a patient with thrombotic thrombocytopenic purpura.
Perrone S; Passucci M; Ortu La Barbera E; Capriata M; Ferretti A; Mecozzi A; Giovangrossi P; Equitani F; Cimino G
J Clin Apher; 2021 Jun; 36(3):499-504. PubMed ID: 33459440
[TBL] [Abstract][Full Text] [Related]
29. Unusual Presentation of Thrombotic Thrombocytopenic Purpura With Non-ST-Elevation Myocardial Infarction.
Gheith Z; Kilani A; Al-Taweel O
Cureus; 2022 Sep; 14(9):e29499. PubMed ID: 36312676
[TBL] [Abstract][Full Text] [Related]
30. Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh-frozen plasma.
Irani MS; Sanchez F; Friedman K
Transfusion; 2020 Aug; 60(8):1666-1668. PubMed ID: 32358818
[TBL] [Abstract][Full Text] [Related]
31. Acute myocardial infarction and extensive systemic thrombosis in thrombotic thrombocytopenic purpura: A case report and review of literature.
Șalaru DL; Adam CA; Marcu DTM; Șimon IV; Macovei L; Ambrosie L; Chirita E; Sascau RA; Statescu C
World J Clin Cases; 2021 Sep; 9(27):8104-8113. PubMed ID: 34621868
[TBL] [Abstract][Full Text] [Related]
32. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial).
Estcourt LJ
Transfus Med; 2019 Jun; 29(3):146-148. PubMed ID: 31318128
[TBL] [Abstract][Full Text] [Related]
33. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Cataland S; Knöbl P; Wu H; Artoni A; Westwood JP; Mansouri Taleghani M; Jilma B; Callewaert F; Ulrichts H; Duby C; Tersago D;
N Engl J Med; 2016 Feb; 374(6):511-22. PubMed ID: 26863353
[TBL] [Abstract][Full Text] [Related]
34. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.
Coppo P; Bubenheim M; Azoulay E; Galicier L; Malot S; Bigé N; Poullin P; Provôt F; Martis N; Presne C; Moranne O; Benainous R; Dossier A; Seguin A; Hié M; Wynckel A; Delmas Y; Augusto JF; Perez P; Rieu V; Barbet C; Lhote F; Ulrich M; Rumpler AC; de Witte S; Krummel T; Veyradier A; Benhamou Y
Blood; 2021 Feb; 137(6):733-742. PubMed ID: 33150928
[TBL] [Abstract][Full Text] [Related]
35. How Should Complicated Cases of Thrombotic Thrombocytopenic Purpura With Positive Coombs Test Be Treated?
Ghrewati M; Mahmoud A; Beliani T; Zakharia K; Kumar M
Cureus; 2023 Dec; 15(12):e50742. PubMed ID: 38234934
[TBL] [Abstract][Full Text] [Related]
36. [Diagnosis and treatment of thrombotic thrombocytopenic purpura].
Kubo M; Matsumoto M
Rinsho Ketsueki; 2020; 61(5):529-535. PubMed ID: 32507820
[TBL] [Abstract][Full Text] [Related]
37. Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective.
Pollissard L; Leinwand BI; Fournier M; Pham HP
J Med Econ; 2021; 24(1):1178-1184. PubMed ID: 34643472
[TBL] [Abstract][Full Text] [Related]
38. [Thrombotic thrombocytopenic purpura].
Yoshitaka M
Rinsho Ketsueki; 2021; 62(5):430-434. PubMed ID: 34108326
[TBL] [Abstract][Full Text] [Related]
39. Does Caplacizumab for the management of thrombotic thrombocytopenic purpura increase the risk of relapse, exacerbation, and bleeding? An updated systematic review and meta-analysis based on revised criteria by the International Working Group for thrombotic thrombocytopenic purpura.
Neupane N; Thapa S; Mahmoud A; Bhattarai A; Kc A; Shikhrakar S; Gurusinghe S; Kuiodes P
EJHaem; 2024 Feb; 5(1):178-190. PubMed ID: 38406548
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study.
Scully M; de la Rubia J; Pavenski K; Metjian A; Knöbl P; Peyvandi F; Cataland S; Coppo P; Kremer Hovinga JA; Minkue Mi Edou J; De Passos Sousa R; Callewaert F; Gunawardena S; Lin J
J Thromb Haemost; 2022 Dec; 20(12):2810-2822. PubMed ID: 36138517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
